Febrile neutropenia in real oncology hospital practice: frequency, risk factors, and prevention assessment

View at publisher Summarise with VIRAT
Authors: G. A. Gromova
Cited by: 0
References: 11

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

A retrospective analysis of data from 3,655 patients who received chemotherapy at a regional oncology dispensary revealed that the incidence of febrile neutropenia (FN) in 2024 was 0.9 %. Among patients with laboratory-confirmed leukopenia (n = 42), FN occurred in 38 %. Prophylactic use of granulocyte colony-stimulating factor (G-CSF) was documented in 45 % of cases within the high-risk group. The findings demonstrate a significant gap between clinical practice and international guidelines, emphasizing the need to implement standardized algorithms for risk assessment and G-CSF administration supported by clinical decision support systems (CDSS).

Fields of Study & Subjects

Neutropenia and Cancer Infections Blood disorders and treatments Antifungal resistance and susceptibility

Publication details

Journal / source
Glavvrač (Chief Medical Officer)
Issue
2
Pages
21–27
Publication date
27 February 2026
Language
EN